A
Angiex
Angiex was founded by world-class scientists to develop vascular-targeted biotherapeutics
About Angiex
Angiex, Inc. is a biotechnology company focused on developing innovative therapies to combat cancer. The company operates in the healthcare and pharmaceutical market, specifically targeting solid tumors with its unique vascular-targeted antibody drug conjugate (ADC) therapy. Angiex's core product aims to significantly reduce cancer mortality by 90%, addressing a critical need in cancer treatment. The company serves patients diagnosed with cancer, healthcare providers, and pharmaceutical partners. Angiex's business model revolves around research and development, clinical trials, and eventual commercialization of its ADC therapy. The company generates revenue through funding rounds, partnerships, and future sales of its therapeutic products. Recent funding includes a $3 million seed preferred financing led by Peter Thiel, with participation from Starling Ventures, WS Investments, and Wild Ventures. This capital is being utilized to advance their vascular approach to cancer therapy.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2015
- Headquarters
- Cambridge, United States
- Employees
- 10
- Open positions
- None listed
- Dealroom signal
- 57.3/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Cardiology and cardiovascular, Spinout, Space Tech, Biotech and Pharma, Space Tech for Health, Space Downstream, DT and LS, science-based
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VC✓Equity / VC | Nov 2025 | $0 | — | Undisclosed | ↗ |
| LATE VC✓Equity / VC | Aug 2025 | $11M | $125M | Undisclosed | ↗ |
Growth signals
Latest recorded traffic for Angiex is 2.6K monthly website visits, up 52.9% over the last three months. Angiex's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
MassChallenge
Series A2 investors entered at this stage
Presight Capital
Thiel Capital
Other known investors4 additional known investors
Beth Israel Deaconess Medical Center
Harvard Medical School
Green Meadow Ventures
Spacestation Investments
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Angiex on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Angiex’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.